Perrigo Company Plc (NYSE:PRGO) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET

Company Participants

Murray Kessler - President, Chief Executive Officer

Eduardo Bezerra - Executive Vice President, Chief Financial Officer

Brad Joseph - Vice President, Investor Relations

Conference Call Participants

Chris Neamonitis - Jefferies

Elliot Wilbur - Raymond James

Chris Schott - JP Morgan

Operator

Good morning and welcome to the Perrigo second quarter 2022 financial results conference call.

All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today’s presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touchtone phone. To withdraw from the question queue, please press star then two. Please note this event is being recorded.

I would now like to turn the conference over to Brad Joseph, VP Investor Relations. Please go ahead.

Brad Joseph

Good morning and welcome to Perrigo’s second quarter 2022 earnings conference call. I hope you all had a chance to review the earnings press release we issued this morning. A copy of the earnings release and presentation for today’s discussion are available within the Investors section of perrigo.com website.

Joining today’s call are President and CEO, Murray Kessler, and recently appointed CFO, Eduardo Bezerra. Welcome, Eduardo.

I’d like to remind everyone that during this call, participants will make certain forward-looking statements. Please refer to the important information for shareholders and investors and Safe Harbor language regarding these statements in our press release issued earlier this morning.

A few quick items before we start. First, unless stated, all financial results discussed and presented are on a continuing operations basis. They do not include any contributions from the divested Rx business, which was accounted for as discontinued operations prior to its sale. In addition to other non-GAAP adjustments as described in the appendix, adjusted profit measures including adjusted EPS and adjusted operating income exclude from the prior year period certain costs incurred to support the operations of the Rx business which were reported in continuing operations. See the appendix for additional details and for reconciliations of all non-GAAP financial measures presented.

Second, organic growth excludes acquisitions, divestitures, and currency in both comparable periods; and third, management’s discussion will focus solely on non-GAAP results except as otherwise expressly noted.

Now I would like to turn the call over to Murray.